ATP9A: A Potential Drug Target and Biomarker (G10079)

Target Name: ATP9A

NCBI ID: G10079

ATP9A

ATP9A: A Potential Drug Target and Biomarker

ATP (adenosine triphosphate) is a crucial molecule in the cell's energy metabolism. It is a small molecule that plays a vital role in the transfer of energy from the cell's energy sources to its needs. ATP is synthesized from the amino acids adenine, guanine, and phosphate. It is widely used in various cellular processes, including muscle contractions, smooth muscle relaxation, and platelet aggregation.

ATP has also been identified as a potential drug target and biomarker. The high-throughput screening (HTS) assay, a powerful tool for drug discovery, has revealed that ATP is a potent inhibitor of protein tyrosine kinase (PTK), a family of enzymes involved in cell signaling pathways. Specifically, ATP inhibits the activity of several PTKs, including FGFR1, PDGFR1, TRK5, and CSK6.

The ATP inhibition of PTKs led to the collapse of several signaling pathways, including the TGF-β pathway, which is involved in cell growth, angiogenesis, and tissue repair. Additionally, the inhibition of PTKs led to the inhibition of the production of new proteins, including proteins involved in cell adhesion, migration, and invasion.

Furthermore, recent studies have shown that ATP can also be used as a biomarker for various diseases, including cancer. In cancer, the levels of ATP are often elevated, and the inhibition of ATP has been shown to be effective in slowing the growth of cancer cells.

The potential drug target of ATP is based on its unique mechanism of action. Unlike most drugs, which target specific proteins and have well-defined binding sites, ATP inhibits multiple PTKs, leading to a more broad and unpredictable effect on cellular signaling pathways. This makes ATP an attractive drug target for cancer therapy.

In addition to its potential as a drug target, ATP has also been shown to be a potential biomarker for various diseases. The levels of ATP have been shown to be elevated in various diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Additionally, the levels of ATP have been shown to be decreased in diseases associated with inflammation, such as rheumatoid arthritis and inflammatory bowel disease.

In conclusion, ATP is a versatile molecule that has been identified as a potential drug target and biomarker. Its inhibition of PTKs and its effects on cellular signaling pathways make it an attractive target for cancer therapy. Additionally, its potential as a biomarker for various diseases make it an important tool in the development of new diagnostic tools and therapies. Further research is needed to fully understand the potential of ATP as a drug and biomarker.

Protein Name: ATPase Phospholipid Transporting 9A (putative)

Functions: Plays a role in regulating membrane trafficking of cargo proteins, namely endosome to plasma membrane recycling and endosome to trans-Golgi network retrograde transport (PubMed:27733620, PubMed:30213940). In complex with MON2 and DOP1B, regulates SNX3 retromer-mediated endosomal sorting of WLS, a transporter of Wnt morphogens in developing tissues. Participates in the formation of endosomal carriers that direct WLS trafficking back to Golgi, away from lysosomal degradation (PubMed:30213940). Appears to be implicated in intercellular communication by negatively regulating the release of exosomes (PubMed:30947313). The flippase activity towards membrane lipids and its role in membrane asymmetry remains to be proved (PubMed:30947313)

The "ATP9A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP9A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets